Generic Lipitor sales push Ranbaxy Q1 profit

Drug maker on Wednesday said its first-quarter consolidated net profit surged by 310 per cent to Rs 1,247 crore, from Rs 304 crore a year earlier, on strong growth in US sales. Net sales for the three months to March rose to Rs 3,695 crore, from Rs 2,141 crore in the year-ago quarter.

Sales in North America were at Rs 2,093 crore, compared to Rs 769 crore a year earlier. Exclusive sales of generic improved the company’s sales in the US market. The company also earned Rs 345 crore in foreign exchange gains.

Ranbaxy launched generic Lipitor in the US in December 2011, followed by European markets. Besides Pfizer, Ranbaxy and are allowed to sell generic Lipitor in the US till May 31.

Managing director and chief executive officer said, “The focus on key products and markets, while maintaining emphasis on further strengthening quality and compliance standards, has had a positive impact on the performance of Ranbaxy.”

HELPED BY LIPITOR
Ranbaxy Laboratories, India's top drugmaker by sales, reported a four-fold rise in quarterly net profit, helped by sales of its generic version of cholesterol drug Lipitor in its key US market, sending its shares up more than 4.5% 
Sales
Q1/ 2011 Rs 2,145cr
Q1/ 2012 Rs 3,700cr
Growth 55%
PAT*
Q1/ 2011 Rs 304cr
Q1/ 2012 Rs 1,247cr
Growth 310%
*Profit after tax
Source: Company, Reuters

Sales in Europe and CIS countries stood at Rs 507 crore, against Rs 455 crore.

Ranbaxy shares on Wednesday closed 3.8 per cent higher at Rs 512.45 on the Bombay Stock Exchange.

image
Business Standard
177 22
Business Standard

Generic Lipitor sales push Ranbaxy Q1 profit

BS Reporter  |  Mumbai 



Drug maker on Wednesday said its first-quarter consolidated net profit surged by 310 per cent to Rs 1,247 crore, from Rs 304 crore a year earlier, on strong growth in US sales. Net sales for the three months to March rose to Rs 3,695 crore, from Rs 2,141 crore in the year-ago quarter.

Sales in North America were at Rs 2,093 crore, compared to Rs 769 crore a year earlier. Exclusive sales of generic improved the company’s sales in the US market. The company also earned Rs 345 crore in foreign exchange gains.

Ranbaxy launched generic Lipitor in the US in December 2011, followed by European markets. Besides Pfizer, Ranbaxy and are allowed to sell generic Lipitor in the US till May 31.

Managing director and chief executive officer said, “The focus on key products and markets, while maintaining emphasis on further strengthening quality and compliance standards, has had a positive impact on the performance of Ranbaxy.”

HELPED BY LIPITOR

Ranbaxy Laboratories, India's top drugmaker by sales, reported a four-fold rise in quarterly net profit, helped by sales of its generic version of cholesterol drug Lipitor in its key US market, sending its shares up more than 4.5% 
Sales
Q1/ 2011 Rs 2,145cr
Q1/ 2012 Rs 3,700cr
Growth 55%
PAT*
Q1/ 2011 Rs 304cr
Q1/ 2012 Rs 1,247cr
Growth 310%
*Profit after tax
Source: Company, Reuters

Sales in Europe and CIS countries stood at Rs 507 crore, against Rs 455 crore.

Ranbaxy shares on Wednesday closed 3.8 per cent higher at Rs 512.45 on the Bombay Stock Exchange.

RECOMMENDED FOR YOU

Generic Lipitor sales push Ranbaxy Q1 profit

Drug maker Ranbaxy Laboratories on Wednesday said its first-quarter consolidated net profit surged by 310 per cent to Rs 1,247 crore, from Rs 304 crore a year earlier, on strong growth in US sales. Net sales for the three months to March rose to Rs 3,695 crore, from Rs 2,141 crore in the year-ago quarter.

Drug maker on Wednesday said its first-quarter consolidated net profit surged by 310 per cent to Rs 1,247 crore, from Rs 304 crore a year earlier, on strong growth in US sales. Net sales for the three months to March rose to Rs 3,695 crore, from Rs 2,141 crore in the year-ago quarter.

Sales in North America were at Rs 2,093 crore, compared to Rs 769 crore a year earlier. Exclusive sales of generic improved the company’s sales in the US market. The company also earned Rs 345 crore in foreign exchange gains.

Ranbaxy launched generic Lipitor in the US in December 2011, followed by European markets. Besides Pfizer, Ranbaxy and are allowed to sell generic Lipitor in the US till May 31.

Managing director and chief executive officer said, “The focus on key products and markets, while maintaining emphasis on further strengthening quality and compliance standards, has had a positive impact on the performance of Ranbaxy.”

HELPED BY LIPITOR
Ranbaxy Laboratories, India's top drugmaker by sales, reported a four-fold rise in quarterly net profit, helped by sales of its generic version of cholesterol drug Lipitor in its key US market, sending its shares up more than 4.5% 
Sales
Q1/ 2011 Rs 2,145cr
Q1/ 2012 Rs 3,700cr
Growth 55%
PAT*
Q1/ 2011 Rs 304cr
Q1/ 2012 Rs 1,247cr
Growth 310%
*Profit after tax
Source: Company, Reuters

Sales in Europe and CIS countries stood at Rs 507 crore, against Rs 455 crore.

Ranbaxy shares on Wednesday closed 3.8 per cent higher at Rs 512.45 on the Bombay Stock Exchange.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard